Presented at ESMO: the POTOMAC study on immunotherapy in non-muscle-invasive bladder cancer
About this episode
Neal Shore joins Ben Abbott of The Lancet to discuss the phase 3 POTOMAC trial of durvalumab plus BCG in BCG-naïve, high-risk non-muscle-invasive bladder cancer, which is being presented at ESMO 2025.
Click here to read the full article
Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv
Get every episode summarized
Each time The Lancet in conversation with publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.
Email me new episodesFree for 3 shows. No card needed.
Hosts & guests
No transcript yet
This episode has not been transcribed. Request it and it moves to the front of the queue.
More episodes
More from The Lancet in conversation with
Louise Chappell and Na'ama Carlin on Personal Cancer Stories
The Lancet in conversation with
Susannah Stanway on the London Global Cancer Week
The Lancet in conversation with
Carlos Monteiro, Camila Corvalán, and Phil Baker on Ultra-Processed Foods and Hu...
The Lancet in conversation with
Presented at ASH: the EPCORE FL-1 study on epcoritamab in follicular lymphoma
The Lancet in conversation with